What Rescheduling Cannabis to Schedule III Would Actually Change
A plain look at what moving cannabis from Schedule I to Schedule III would mean for businesses, patients, and everyday consumers.
TL;DR
Moving cannabis to Schedule III would not make it federally legal, but it would remove a tax penalty that has squeezed the industry for years and open the door to more research. It would not automatically fix banking access, expunge records, or protect state-legal sellers from federal law. The proposal is still working through a federal review process and is not final.
What Rescheduling Cannabis to Schedule III Would Actually Change
Moving cannabis from Schedule I to Schedule III would not legalize it federally. It would reclassify the drug as one with accepted medical use and lower abuse potential, which mainly changes how businesses are taxed and loosens restrictions on research. What it would not do is make state dispensaries legal under federal law, fix the banking mess, or clear anyone's criminal record.
The push started with a 2023 recommendation from the U.S. Department of Health and Human Services, which the DEA then picked up for its own review. Nothing is final yet. The rulemaking process still includes a public comment period and possibly administrative hearings before any of this actually takes effect.
What is the Controlled Substances Act schedule system?
The federal government sorts controlled substances into five schedules under the Controlled Substances Act, based on accepted medical use and potential for abuse.
Schedule I is the most restrictive tier, reserved for substances the government says have no accepted medical use and a high potential for abuse. Cannabis has sat there next to heroin since 1970.
Schedule III sits in the middle. It covers substances with recognized medical use and moderate to low potential for physical dependence. Ketamine, anabolic steroids, and products with small amounts of codeine all live there.
Shifting cannabis to Schedule III is a formal admission that it has medical value. That carries real legal weight, even if it falls well short of legalization.
What would actually change under Schedule III?
The biggest immediate effect is tax. A provision of the federal tax code called Section 280E bars businesses that traffic in Schedule I or II substances from deducting ordinary costs like rent and payroll.
Because cannabis sits in Schedule I, licensed operators have been paying federal tax on gross profit instead of net profit, something industry groups and tax professionals generally say produces a far heavier effective tax burden than most other industries carry. Section 280E only applies to Schedule I and II substances, so a move to Schedule III would lift that penalty.
Research would get easier too. Studying a Schedule I substance requires a demanding federal registration process that has slowed clinical work for decades. Schedule III drugs are studied under far more common protocols, which could open the door to a much larger body of research on cannabis for medical use.
Want this working on your numbers?
TNM News makes marketing you can prove, matched to real, closed sales.
What would not change?
State-legal dispensaries would still be operating outside federal law. Schedule III substances need a prescription and FDA approval to be sold legally, and the products sold in state cannabis markets do not meet that bar. So the current retail model would stay federally unauthorized, full stop.
Banking would not automatically get easier. Most banks steer clear of cannabis businesses because of federal illegality and money-laundering exposure, and rescheduling alone does not touch those rules. That would take separate legislation, the kind of thing often discussed under the SAFER Banking Act.
Criminal records would not clear either. Rescheduling isn't retroactive and doesn't expunge past convictions. Record relief has to come through separate state and federal action.
How does this affect everyday consumers?
For most consumers, a trip to the dispensary would probably look the same in the short term. Products, menus, and state rules aren't going to shift overnight.
One possible longer-term effect is lower prices, since operators would no longer be taxed on expenses they couldn't deduct before. But nothing forces companies to pass those savings on to customers, and there's no way to predict or promise a specific price drop.
More research could eventually mean better labeling and clearer guidance on dosing and effects, but that depends on studies that haven't happened yet and could take years to finish.
When would rescheduling take effect?
There's no fixed date. Federal rulemaking involves a proposed rule, a public comment period, and in this case a request for an administrative hearing before a judge, any of which can stretch the timeline out considerably.
The process can also stall or change direction with shifts in administration and agency priorities. Until a final rule is published and takes effect, cannabis stays a Schedule I substance under federal law.
Anyone making business or personal decisions around this should treat it as proposed, not settled.
What should businesses and consumers watch for?
Businesses should keep an eye on the final DEA rule and any guidance on how 280E relief would apply to a given tax year. Timing matters here, since the tax change kicks in based on when rescheduling becomes final, not when it was first proposed.
Consumers should pay attention to their own state's rules, since those govern what they can legally buy and possess no matter what happens at the federal level. State law is what applies at the register.
Both sides should be wary of anyone claiming rescheduling equals legalization. It doesn't, and treating it that way can lead to some expensive mistakes.
Cannabis law varies by state and changes frequently. Confirm the current rules in your own state and consult a qualified professional before acting on anything in this article.
Sources
- Federal Register: Schedules of Controlled Substances: Rescheduling of Marijuana; Withdrawal
- Federal Register: Schedules of Controlled Substances: Rescheduling of Marijuana (Notice of Hearing, Aug 29, 2024)
- 21 U.S.C. § 812 - Controlled Substances Act Schedules
- Treasury/IRS Press Release: Process for Tax Guidance Following DOJ Final Order on Medical Marijuana Rescheduling
TNM News Staff
TNMNStaff is our general staff who contribute to our content. We are here to share news, entertainment, and culture without the need for personal recognition.